Syndax Pharmaceuticals, Inc. (SNDX)
9.54
+0.17
(+1.81%)
USD |
NASDAQ |
Nov 06, 16:00
9.79
+0.25
(+2.62%)
After-Hours: 20:00
Syndax Pharmaceuticals Research and Development Expense (Quarterly) : 67.48M for Sept. 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 67.48M |
| June 30, 2026 | 68.03M |
| March 31, 2026 | 58.84M |
| December 31, 2025 | 78.64M |
| September 30, 2025 | 56.28M |
| June 30, 2025 | 62.23M |
| March 31, 2025 | 61.64M |
| December 31, 2024 | 65.53M |
| September 30, 2024 | 70.97M |
| June 30, 2024 | 48.65M |
| March 31, 2024 | 56.49M |
| December 31, 2023 | 55.12M |
| September 30, 2023 | 39.08M |
| June 30, 2023 | 34.61M |
| March 31, 2023 | 33.94M |
| December 31, 2022 | 31.73M |
| September 30, 2022 | 26.79M |
| June 30, 2022 | 29.62M |
| March 31, 2022 | 29.90M |
| December 31, 2021 | 23.78M |
| September 30, 2021 | 25.49M |
| June 30, 2021 | 16.77M |
| March 31, 2021 | 21.75M |
| December 31, 2020 | 15.40M |
| September 30, 2020 | 14.38M |
| Date | Value |
|---|---|
| June 30, 2020 | 10.92M |
| March 31, 2020 | 9.539M |
| December 31, 2019 | 9.502M |
| September 30, 2019 | 9.923M |
| June 30, 2019 | 12.29M |
| March 31, 2019 | 11.28M |
| December 31, 2018 | 15.82M |
| September 30, 2018 | 14.10M |
| June 30, 2018 | 14.85M |
| March 31, 2018 | 15.34M |
| December 31, 2017 | 16.60M |
| September 30, 2017 | 12.19M |
| June 30, 2017 | 9.862M |
| March 31, 2017 | 9.552M |
| December 31, 2016 | 8.474M |
| September 30, 2016 | 12.27M |
| June 30, 2016 | 6.131M |
| March 31, 2016 | 4.786M |
| September 30, 2014 | 1.709M |
| June 30, 2014 | |
| March 31, 2014 | 2.137M |
| December 31, 2013 | 0.633M |
| September 30, 2013 | |
| March 31, 2013 | 0.573M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 76.28M |
| Emergent BioSolutions, Inc. | 7.50M |
| Incyte Corp. | 1.774B |
| Vertex Pharmaceuticals, Inc. | 1.321B |
| Travere Therapeutics, Inc. | 70.30M |